My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Abbott Laboratories (NY:ABT)

112.68 +1.21 (+1.09%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Abbott Laboratories

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

47 48 Next >

How Is The Market Feeling About Abbott Laboratories? ↗

March 28, 2024

Via Benzinga

Performance Comparison: Abbott Laboratories And Competitors In Health Care Equipment & Supplies Industry ↗

March 27, 2024

Via Benzinga

Winning Over Wall Street: 3 Stocks Earning Overwhelming Analyst Approval ↗

March 26, 2024

Discover the investment potential of three stocks with analyst approval for their robust financials and strategic market positions.

Via InvestorPlace

More Than 86% of Analysts Who Cover These 3 Stocks Rate Them a ‘Buy’ ↗

March 25, 2024

Investors should take notice of these stocks with high analyst ratings. It's time to load up your portfolio.

Via InvestorPlace

Want Decades of Passive Income? 2 Stocks to Buy Now. ↗

March 22, 2024

There aren't many guarantees in the equity market, but the dividend payouts of Johnson & Johnson and Abbott Laboratories may be as close as it gets to a sure thing.

Via The Motley Fool

3 Stocks to Buy Right Now for the Coming Recession ↗

March 21, 2024

With numerous economic indicators souring, these three stocks to buy for a recession will protect your portfolio's downside.

Via InvestorPlace

Topics Economy

What the Options Market Tells Us About Abbott Laboratories ↗

March 19, 2024

Via Benzinga

$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today ↗

March 08, 2024

Via Benzinga

Is Abbott Laboratories a Top Dividend Growth Stock to Buy Now? ↗

March 07, 2024

Abbott Laboratories has been growing its dividend at a blistering pace. Is its stock a buy?

Via The Motley Fool

3 Resilient Stocks to Protect Your Wealth During a Recession ↗

March 21, 2024

Discover three recession-resistant stocks with growth leads in the consumer staples, household products, and healthcare industries.

Via InvestorPlace

What's Going On With Abbott Laboratories Stock On Friday? ↗

March 15, 2024

An Illinois jury orders Reckitt Benckiser's Mead Johnson to pay $60 million after a premature infant's tragic death linked to Enfamil baby formula. Mead Johnson found negligent for not warning about...

Via Benzinga

Topics Lawsuit

Why Abbott's Formula-Related Sell-Off Could Be A Buying Opportunity, Says Analyst ↗

March 15, 2024

Fellow infant formula maker Reckitt Benckiser was ordered to pay $60 million to a mother whose baby died after eating Enfamil.

Via Investor's Business Daily

Topics Death

SCHD ETF Spotlight: The Top 6 Stocks Inside This Dividend Monster ↗

March 13, 2024

With over 100 dividend growth stocks in its portfolio, the SCHD ETF has proved to be a formidable income-generating vehicle for investors.

Via InvestorPlace

Topics ETFs

3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March ↗

March 11, 2024

These are some of the best-performing stocks in what's arguably society's most important industry.

Via The Motley Fool

Exploring ABBOTT LABORATORIES (NYSE:ABT)s quality characteristics. ↗

March 05, 2024

Why the quality investor may take a look at ABBOTT LABORATORIES (NYSE:ABT).

Via Chartmill

$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today ↗

March 01, 2024

Via Benzinga

Could Abbott Laboratories Stock Help You Become a Millionaire? ↗

February 26, 2024

Abbott's earnings have soared over the past decade.

Via The Motley Fool

FDA Approval For DexCom's Stelo Opens Continuous Glucose Monitoring To Masses, Analyst Expects Competitive Pricing Against Abbott's ↗

March 06, 2024

FDA greenlights DexCom's Stelo, the first OTC continuous glucose monitor for non-insulin-dependent diabetics. Competitive pricing, potential HSA benefits, and market expansion make it a significant...

Via Benzinga

3 Dividend Aristocrats With the Largest 10-Year Dividend Growth Rates ↗

March 06, 2024

These three dividend stocks have proved themselves to be among the best Dividend Aristocrats to buy for high-growth returns.

Via InvestorPlace

Why Dexcom — And The Obesity Market — Could Benefit From This New FDA Win ↗

March 06, 2024

The FDA granted Dexcom's Stelo a broad clearance, meaning people without diabetes can use it.

Via Investor's Business Daily

Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite ↗

March 03, 2024

There is a world of opportunities ahead for this healthcare giant.

Via The Motley Fool

Nearing Retirement? These Stocks Are as Cautious as They Come ↗

February 28, 2024

Healthcare blue chips can provide retirees the consistency they need while growing their nest eggs further.

Via The Motley Fool

Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment ↗

February 23, 2024

Via Benzinga

Peering Into Abbott Laboratories's Recent Short Interest ↗

February 20, 2024

Via Benzinga

3 Magnificent Dividend Growth Stocks to Buy Now and Hold for at Least a Decade ↗

February 27, 2024

These stocks don't offer the highest yields, but their payouts are growing fast.

Via The Motley Fool

3 Blue-Chip Stocks to Buy to Bolster Your Portfolio ↗

February 26, 2024

Delve into three undervalued blue-chip stocks to buy driving growth in consumer staples, pharmaceuticals, and healthcare.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 26, 2024

Via Benzinga

Looking for Growth? 7 Hot Trends That Have Been Flying Under Investors’ Radar. ↗

February 26, 2024

Discover 7 under-the-radar stock trends set to make waves in the stock market. Find out why savvy investors are tuning in.

Via InvestorPlace

Recession-Proof Riches: 7 Stocks to Buy for Bulletproof Portfolio Growth ↗

February 23, 2024

Explore recession-proof stocks thriving in Energy, Health Care, Industrials, and more, offering stability and growth amid economic turmoil.

Via InvestorPlace

Abbott Laboratories Stock Gets A Healthy Technical Rating Upgrade ↗

February 21, 2024

In a welcome move, Abbott Laboratories stock saw its Relative Strength Rating improve from 67 to 73 on Wednesday.

Via Investor's Business Daily

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

47 48 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.